Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3028 Download: 189 Web of Science: 8 Crossref: 10

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 3286 Download: 103

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 3515 Download: 171 Web of Science: 8 Crossref: 8

Original Article

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330

View: 2804 Download: 157 Web of Science: 3 Crossref: 3

Editorial

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 2466 Download: 69 Web of Science: 2 Crossref: 2

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2252 Download: 92 Web of Science: 2 Crossref: 1

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 3513 Download: 135 Web of Science: 4 Crossref: 4

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 2274 Download: 61

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 6684 Download: 482 Web of Science: 40 Crossref: 41

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 2921 Download: 89

Original Article

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 6654 Download: 222 Web of Science: 11 Crossref: 16

Review

Recent research trends and updates on nonalcoholic fatty liver disease

Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn

Clin Mol Hepatol. 2019;25(1):1-11. Published online August 8, 2018

DOI: https://doi.org/10.3350/cmh.2018.0037

View: 18520 Download: 716 Web of Science: 69 Crossref: 66

Original Article

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis

Wataru Ando, Hiroaki Yokomori, Nobuhiro Tsutsui, Eigoro Yamanouchi, Yutaka Suzuki, Masaya Oda, Yutaka Inagaki, Katsuya Otori, Isao Okazaki

Clin Mol Hepatol. 2018;24(1):61-76. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0030

View: 9192 Download: 170 Web of Science: 25 Crossref: 27

Case Report

Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy

Eun Hui Sim, Jung Hyun Kwon, Se Young Kim, Seung Min Jung, Lee-So Maeng, Jeong Won Jang, Kyu Won Chung

Clin Mol Hepatol. 2012;18(4):404-410. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.404

View: 7236 Download: 83 Crossref: 13

3

Validity and reliability of the nonalcoholic fatty Liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors

Kyung-Hun Lee, M.D., Sang Hoon Park, M.D., Yu Jin Kim, M.D., Kyung Rim Huh, M.D., Kwang Seon Min M.D., Sun-Young Jun M.D., Kyoung Oh Kim, M.D., Cheol Hee Park, M.D., Taeho Hahn, M.D., Kyo-Sang Yoo, M.D., Jong Hyeok Kim, M.D., Myung-Seok Lee, M.D., Choong Kee Park, M.D.

Clin Mol Hepatol. 2010;16(1):29-37. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.29

View: 5026 Download: 52 Crossref: 2

Current status of Liver diseases in Korea: nonalcoholic fatty Liver disease

Sang Hoon Park

Clin Mol Hepatol. 2009;15(60):34-39. Published online December 31, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S34

View: 7101 Download: 45 Crossref: 19

2

Pathology of nonalcoholic steatohepatitis

Yoon Mi Jeen , So Young Jin

Clin Mol Hepatol. 2009;15(2):122-130. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.122

View: 4993 Download: 56 Crossref: 3

5

Nonalcoholic Steatohepatitis

So-Young Jin

Clin Mol Hepatol. 2006;12(3):455-459. Published online January 1, 2000

View: 2541 Download: 20

3

Antioxidant Status in Nonalcoholic Steatohepatitis

Kyung Sik Park, M.D., Byoung Kuk Jang, M.D., Ki Min Kwon, M.D., Woo Jin Chung, M.D., Kwang Bum Cho, M.D., Jae Seok Hwang, M.D., Sung Hoon Ahn, M.D., Kyo Cheol Mun, M.D. and Young Hwan Kim, M.D.

Clin Mol Hepatol. 2005;11(2):135-143. Published online January 1, 2000

View: 2565 Download: 26

Relationship between the Severity of Liver Damage and the Serum Leptin Level for Nonalcoholic Fatty Liver Disease

Kyoung Oh Kim, M.D., Sang Hoon Park, M.D., Cheol Hee Park, M.D., Tai Ho Han, M.D., Kyo-Sang Yoo, M.D., Jong Hyeok Kim, M.D., Myung Seok Lee, M.D., Dong Jun Kim, M.D., Choong Kee Park, and Hyun-Deuk Cho, M.D.

Clin Mol Hepatol. 2005;11(1):51-58. Published online January 1, 1970

View: 2515 Download: 36

The Prevalence of Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease

Ki Won Moon, M.D., Joung Muk Leem, M.D., Sang Seok Bae, M.D., Ki Man Lee, M.D., Seok Hyung Kim, M.D.*, Hee Bok Chae, M.D., Seon Mee Park, M.D. and Sei Jin Youn, M.D.

Clin Mol Hepatol. 2004;10(3):197-206. Published online January 1, 1970

View: 3082 Download: 58

1 |

Viewed By 5178	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5036	MAFLD: How is it different from NAFLD?
Viewed By 4986	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3675	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3629	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search